Work

Benralizumab for Patients With Hypereosinophilic Syndrome: a Randomized, Double-blind, Placebo-controlled Phase 3 Trial (natron)

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of Allergy Asthma & Immunology

DOI: 10.1016/j.anai.2025.10.019

Authors: P. Ogbogu, F. Roufosse, P. Akuthota, P. Lacwik, M. Groh, A. Reiter, A. Yokota, S. Siddiqui, P. Mutsaers, B. Li, L. Bahadori, A. Bednarczyk, G. Bouma, L. Brooks, J. Ferreira, H. Grindebacke, C. Ho, P. Jain, R. Palmer, C. Walton, M. Jison, A. Klion

Language: English

Topic: Eosinophilic Disorders and Syndromes

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415922508

FWCI: 1.894

Cites:

Cited by: 3

Related to: